Regulus Therapeutics Inc.
RGLS · NASDAQ
3/31/2025 | 12/31/2024 | 9/30/2024 | 6/30/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -100% | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | -$0 | -$0 | -$0 | -$0 |
| % Margin | – | -25.6% | – | – |
| R&D Expenses | $7 | $10 | $11 | $8 |
| G&A Expenses | $4 | $4 | $4 | $4 |
| SG&A Expenses | $4 | $4 | $4 | $4 |
| Sales & Mktg Exp. | $0 | $0 | $0 | -$0 |
| Other Operating Expenses | -$0 | -$0 | $0 | $0 |
| Operating Expenses | $10 | $14 | $15 | $12 |
| Operating Income | -$11 | -$14 | -$15 | -$12 |
| % Margin | – | -4,042.9% | – | – |
| Other Income/Exp. Net | $1 | $1 | $1 | $1 |
| Pre-Tax Income | -$10 | -$13 | -$14 | -$11 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$10 | -$13 | -$14 | -$11 |
| % Margin | – | -3,762.1% | – | – |
| EPS | -0.15 | -0.2 | -0.21 | -0.17 |
| % Growth | 25% | 4.8% | -23.5% | – |
| EPS Diluted | -0.15 | -0.2 | -0.21 | -0.17 |
| Weighted Avg Shares Out | 66 | 65 | 65 | 64 |
| Weighted Avg Shares Out Dil | 66 | 65 | 65 | 64 |
| Supplemental Information | – | – | – | – |
| Interest Income | $1 | $1 | $1 | $1 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$10 | -$13 | -$14 | -$11 |
| % Margin | – | -3,732.6% | – | – |